Contact Us / Request a Quote Download Manuals
Advanced Cell Diagnostics Advanced Cell Diagnostics

Search form

Please sign in
  • Log In
  • Register
  • How to Order
  • What to Buy
0 My Cart
X

You have no items in your shopping cart.

Menu
X
  • Products +
    RNAscope™/BaseScope™/ miRNAscope™
    +
    • Assay Selection Guide
    Target Probes
    +
    • All About Probes
    • Catalog Probes
    • Probe Sets
    • New Probe Request
    Manual Assays
    +
    RNAscope™ Chromogenic
    • Overview
    • RNAscope™ 2.5 HD Assay-Brown
    • RNAscope™ 2.5 HD Assay-Red
    • RNAscope™ 2.5 HD Duplex Assay
    RNAscope™ Multiplex Fluorescent
    • Overview
    • RNAscope™ HiPlex v2 Assay
    • RNAscope™ Multiplex Fluorescent V2
    BaseScope™
    • Overview
    • BaseScope™ Assay Red
    • BaseScope™ Duplex Assay
    miRNAscope™
    • Overview
    • miRNAscope™ Assay red
    • RNAscope™ Plus smRNA-RNA Assay
    DNAscope™
    • Overview
    • DNAscope™ Duplex Assay
    Automated Assays
    +
    For Lunaphore COMET™
    • RNAscope™ HiPlex Pro for COMET™
    For Leica systems
    • Overview
    • RNAscope™ 2.5 LS Assay-Brown
    • RNAscope™ 2.5 LS Assay-Red
    • RNAscope™ 2.5 LS Duplex Assay
    • RNAscope™ Multiomic LS Assay
    • RNAscope™ 2.5 LS Fluorescent Multiplex Assay
    • RNAscope™ 2.5 LSx Reagent Kit-BROWN
    • RNAscope™ 2.5 LSx Reagent Kit-RED
    • BaseScope™ LS Reagent Kit – RED
    • miRNAscope LS Reagent Kit Red
    • RNAscope™ Plus smRNA-RNA LS Assay
    Roche DISCOVERY ULTRA system
    • Overview
    • RNAscope™ VS Universal HRP
    • RNAscope™ VS Universal AP
    • RNAscope™ VS Duplex Assay
    • BaseScope™ VS Reagent Kit – RED
    RNA-Protein Co-Detection Assay
    +
    • RNAscope HiPlex-IMC™ Co-Detection
    • Integrated Codetection Assay
    • Sequential RNA Protein Detection
    Software
    +
    • Overview
    • Aperio RNA ISH Algorithm
    • HALO® image analysis platform
    Controls & Accessories
    +
    • RNAscope™
    • BaseScope™
    • miRNAscope™
    • Accessories
    How to Order
    +
    • Ordering Instructions
    • What to Buy
  • Services +
    Professional Assay Services
    +
    • Our Services
    • Multiomic Services
    • Biomarker Assay Development
    • Cell & Gene Therapy Services
    • Clinical Assay Development
    • Tissue Bank & Sample Procurement
    • Image Analysis
    Benefits
    +
    • Your Benefits
    • Certified Providers
    How to Order
    +
    • Ordering Process
    • Contact Services
  • Areas of Research +
    Most Popular
    +
    • COVID-19 Coronavirus
    • Single Cell Analysis
    • Whole-Mount
    • Anatomic Pathology Panels
    • Neuroscience
    • Inflammation
    • Gene Therapy/AAV
    • Stem Cell
    • Immuno-oncology
    • Liver Research
    • Cardiovascular & Skeletal Muscle Research
    Cell & Gene Therapy
    +
    • Gene Therapy
    • Gene Therapy/AAV
    • siRNA/ASO
    • Cell Therapy
    Cancer
    +
    • Breast Cancer
    • EGFRvIII Splice Variant
    • HPV Related Cancer
    • Immuno-oncology
    • Lung Cancer
    • PDx
    • Prostate Cancer
    • Point Mutation
    • CDR3 for TCR
    Viral
    +
    • COVID-19 Coronavirus
    • HIV & SIV
    • Infectious Disease
    • Zika Virus
    Pathways
    +
    • AKT
    • JAK STAT
    • WNT B-Catenin
    Neuroscience
    +
    Neuroscience
    • Neural Development
    • Neuronal Cell Types
    • Learning and Memory
    • G-protein-coupled Receptors & Ion Channels
    • Post-mortem Brain Tissue
    Other
    +
    • Circular RNA
    • Gene Fusions
    • HT Transcript Validation
    • Long Non-coding RNA
    • RNAseq Validation
    • Single Cell Analysis
    • Splice Variant
    • miRNA
    RNA & Protein
    +
    • Antibody Challenges
    • Dual ISH + IHC Methods
    • No Antibodies
    • RNA & Protein Analysis
    Customer Innovations
    +
    • Dual RNA+DNA ISH
    • Very old FFPE ISH
    • Wholemount ISH
    Animal Models
    +
    • Any Species
    • Mouse Model
    • Preclincal Safety
  • Technology +
    Overview
    +
    • How it Works
    • Data Image Gallery
    • Technology Video
    • Webinars
    RNA Detection
    +
    • Why RNA?
    • RNA ISH and IHC
    Pretreatment Options
    +
    • RNAscope™ Pretreatment
    • PretreatPro™
    Spotlights
    +
    • Researchers Spotlights
    • RNA & DNA
    • WISH
    • FFPE
    • Testimonials
    Publications, Guides & Posters
    +
    • Search publications
    • RNAscope™ Reference Guide
    • RNAscope™ Data Analysis Guide
    • Download RNAscope™ Posters
  • Support +
    Overview
    +
    • Get Started
    • How to Order
    • Distributors
    • Contact Support
    Troubleshooting
    +
    • Troubleshooting Guide
    • FAQs
    • User Manuals, SDS and Product Inserts
    • Documents and Downloads
    Imaging Resource
    +
    • Image Analysis
    • Image Registration Software
    • QuPath
    • HALO® image analysis platform
    Learn More
    +
    • Webinars
    • Training Videos
  • Partners +
    Partners
    +
    • Overview
    Partners Directory
    +
    Automation Partners
    • Leica Biosystem
    • Roche Diagnostics
    Workflow Partners
    • NanoString
    Software Partners
    • indica labs
    Become a Partner
    +
    • Learn How
  • Diagnostics +
    Diagnostics
    +
    • Diagnostics
    • Literature
    • Diagnostics ASR Probes
    • Diagnostics CE-IVD Probes
    • Diagnostics CE-IVD Detection
    • Companion Diagnostics
  • Image Calendar +
    Image Calendar
    +
    • Image Contest
    • Data Image Gallery
Search

Probes for LONG

ACD can configure probes for the various manual and automated assays for LONG for RNAscope Assay, or for Basescope Assay compatible for your species of interest.

ACD’s data images for Long gene.

  • RNA expression of long gene in Human Colorectal cancer sample using RNAscope™ 2.5 HD Assay Brown

  • RNA expression of long gene in Human Gastric cancer sample using RNAscope™ 2.5 HD Assay Brown

  • RNA expression of long gene in Human Glioma sample using RNAscope™ 2.5 HD Assay Brown

  • RNA expression of long gene in Human Lung cancer sample using RNAscope™ 2.5 HD Assay Brown

  • RNA expression of long gene in Human ovarian cancer sample using RNAscope™ 2.5 HD Assay Brown

  • Expression of long in Human Prostate cancer sample using RNAscope™ 2.5 HD Assay Brown

  • Probes for Long (25732)
  • Kits & Accessories (0)
  • Support & Documents (0)
  • Publications (368)
  • Image gallery (0)
Refine Probe List

Content for comparison

Gene

  • TBD (57) Apply TBD filter
  • MALAT1 (13) Apply MALAT1 filter
  • H19 (7) Apply H19 filter
  • SARS-CoV-2 (7) Apply SARS-CoV-2 filter
  • HOTAIR (6) Apply HOTAIR filter
  • Neat1 (4) Apply Neat1 filter
  • Slc17a6 (4) Apply Slc17a6 filter
  • Slc17a7 (4) Apply Slc17a7 filter
  • SChLAP1 (4) Apply SChLAP1 filter
  • MEG3 (3) Apply MEG3 filter
  • Gad1 (3) Apply Gad1 filter
  • MMP13 (3) Apply MMP13 filter
  • GFAP (3) Apply GFAP filter
  • PVT1 (3) Apply PVT1 filter
  • Col2a1 (3) Apply Col2a1 filter
  • col10a1 (3) Apply col10a1 filter
  • UCA1 (3) Apply UCA1 filter
  • LINC00473 (3) Apply LINC00473 filter
  • EBER1 (3) Apply EBER1 filter
  • ACTA2 (2) Apply ACTA2 filter
  • GAPDH (2) Apply GAPDH filter
  • Alpl (2) Apply Alpl filter
  • Wnt5a (2) Apply Wnt5a filter
  • ICAM1 (2) Apply ICAM1 filter
  • FOS (2) Apply FOS filter
  • GREM1 (2) Apply GREM1 filter
  • PVALB (2) Apply PVALB filter
  • Sst (2) Apply Sst filter
  • Cdh13 (2) Apply Cdh13 filter
  • PDGFRA (2) Apply PDGFRA filter
  • Gad2 (2) Apply Gad2 filter
  • BCAR4 (2) Apply BCAR4 filter
  • Chat (2) Apply Chat filter
  • CXCL12 (2) Apply CXCL12 filter
  • GAS5 (2) Apply GAS5 filter
  • Pomc (2) Apply Pomc filter
  • CARTPT (2) Apply CARTPT filter
  • Runx2 (2) Apply Runx2 filter
  • TIE1 (2) Apply TIE1 filter
  • vGlut2 (2) Apply vGlut2 filter
  • Pnky (2) Apply Pnky filter
  • PD-L1 (2) Apply PD-L1 filter
  • RAD51-AS1 (2) Apply RAD51-AS1 filter
  • LINC01133 (2) Apply LINC01133 filter
  • LINK-A (2) Apply LINK-A filter
  • LpR2 (2) Apply LpR2 filter
  • LINC00958 (2) Apply LINC00958 filter
  • Lncenc1 (2) Apply Lncenc1 filter
  • ROR (2) Apply ROR filter
  • ELDR (2) Apply ELDR filter

Product

  • RNAscope Multiplex Fluorescent Assay (56) Apply RNAscope Multiplex Fluorescent Assay filter
  • RNAscope (47) Apply RNAscope filter
  • RNAscope 2.0 Assay (44) Apply RNAscope 2.0 Assay filter
  • RNAscope 2.5 HD Red assay (39) Apply RNAscope 2.5 HD Red assay filter
  • RNAscope Fluorescent Multiplex Assay (37) Apply RNAscope Fluorescent Multiplex Assay filter
  • RNAscope 2.5 HD Brown Assay (24) Apply RNAscope 2.5 HD Brown Assay filter
  • BASEscope Assay RED (9) Apply BASEscope Assay RED filter
  • RNAscope 2.5 HD Reagent Kit - BROWN (8) Apply RNAscope 2.5 HD Reagent Kit - BROWN filter
  • RNAscope 2.5 LS Assay (5) Apply RNAscope 2.5 LS Assay filter
  • TBD (5) Apply TBD filter
  • Basescope (3) Apply Basescope filter
  • RNAscope 2.5 HD Duplex (3) Apply RNAscope 2.5 HD Duplex filter
  • RNAscope Multiplex Fluorescent v2 (3) Apply RNAscope Multiplex Fluorescent v2 filter
  • RNAscope 2.5 VS Assay (2) Apply RNAscope 2.5 VS Assay filter
  • DNAscope HD Duplex Reagent Kit (1) Apply DNAscope HD Duplex Reagent Kit filter

Research area

  • Cancer (120) Apply Cancer filter
  • lncRNA (110) Apply lncRNA filter
  • Neuroscience (74) Apply Neuroscience filter
  • LncRNAs (41) Apply LncRNAs filter
  • Development (24) Apply Development filter
  • Infectious Disease (16) Apply Infectious Disease filter
  • Inflammation (12) Apply Inflammation filter
  • Stem Cells (10) Apply Stem Cells filter
  • Covid (9) Apply Covid filter
  • Other (7) Apply Other filter
  • Bone (5) Apply Bone filter
  • Immunotherapy (4) Apply Immunotherapy filter
  • Infectious (4) Apply Infectious filter
  • Developmental (3) Apply Developmental filter
  • HPV (3) Apply HPV filter
  • Kidney (3) Apply Kidney filter
  • Pain (3) Apply Pain filter
  • Stem cell (3) Apply Stem cell filter
  • Alzheimer's Disease (2) Apply Alzheimer's Disease filter
  • Autism (2) Apply Autism filter
  • CGT (2) Apply CGT filter
  • Endocrinology (2) Apply Endocrinology filter
  • Heart (2) Apply Heart filter
  • Injury (2) Apply Injury filter
  • Long Covid (2) Apply Long Covid filter
  • Metabolism (2) Apply Metabolism filter
  • osteoarthritis (2) Apply osteoarthritis filter
  • Other: Cell Biology (2) Apply Other: Cell Biology filter
  • Age-related macular degeneration (1) Apply Age-related macular degeneration filter
  • Aging (1) Apply Aging filter
  • Circadian clock (1) Apply Circadian clock filter
  • Feeding Behavior (1) Apply Feeding Behavior filter
  • Hearing (1) Apply Hearing filter
  • HIV (1) Apply HIV filter
  • Huntington's Disease (1) Apply Huntington's Disease filter
  • Infectious Disease: Ebola virus disease (1) Apply Infectious Disease: Ebola virus disease filter
  • Influenza A (1) Apply Influenza A filter
  • Jet Leg (1) Apply Jet Leg filter
  • Lnc (1) Apply Lnc filter
  • Lung (1) Apply Lung filter
  • Metabolic (1) Apply Metabolic filter
  • MicroRNAs (1) Apply MicroRNAs filter
  • Other: Eyes (1) Apply Other: Eyes filter
  • Other: Genomics (1) Apply Other: Genomics filter
  • Other: Heart (1) Apply Other: Heart filter
  • Other: Kidney (1) Apply Other: Kidney filter
  • Other: Liver (1) Apply Other: Liver filter
  • Other: Methods (1) Apply Other: Methods filter
  • Regeneration (1) Apply Regeneration filter
  • Skin (1) Apply Skin filter

Category

  • Publications (368) Apply Publications filter
An H2R-dependent medial septum histaminergic circuit mediates feeding behavior

Current biology : CB

2022 Mar 23

Xu, L;Lin, W;Zheng, Y;Chen, J;Fang, Z;Tan, N;Hu, W;Guo, Y;Wang, Y;Chen, Z;
PMID: 35338850 | DOI: 10.1016/j.cub.2022.03.010

Novel targets for treating feeding-related diseases are of great importance, and histamine has long been considered an anorexigenic agent. However, understanding its functions in feeding in a circuit-specific way is still limited. Here, we report a medial septum (MS)-projecting histaminergic circuit mediating feeding behavior. This MS-projecting histaminergic circuit is functionally inhibited during food consumption, and bidirectionally modulates feeding behavior via downstream H2, but not H1, receptors on MS glutamatergic neurons. Further, we observed a pathological decrease of histamine 2 receptors (H2Rs) expression in MS glutamatergic neurons in diet-induced obesity (DIO) mice. Genetically, down-regulation of H2Rs expression in MS glutamatergic neurons accelerates body-weight gain. Importantly, chronic activation of H2Rs in MS glutamatergic neurons (with its clinical agonist amthamine) significantly slowed down the body-weight gain in DIO mice, providing a possible clinical utility to treat obesity. Together, our results demonstrate that this MS-projecting histaminergic circuit is critically involved in feeding, and H2Rs in MS glutamatergic neurons is a promising target for treating body-weight problems.
A neomorphic variant in SP7 alters sequence specificity and causes a high-turnover bone disorder

Nature communications

2022 Feb 04

Lui, JC;Raimann, A;Hojo, H;Dong, L;Roschger, P;Kikani, B;Wintergerst, U;Fratzl-Zelman, N;Jee, YH;Haeusler, G;Baron, J;
PMID: 35121733 | DOI: 10.1038/s41467-022-28318-4

SP7/Osterix is a transcription factor critical for osteoblast maturation and bone formation. Homozygous loss-of-function mutations in SP7 cause osteogenesis imperfecta type XII, but neomorphic (gain-of-new-function) mutations of SP7 have not been reported in humans. Here we describe a de novo dominant neomorphic missense variant (c.926 C > G:p.S309W) in SP7 in a patient with craniosynostosis, cranial hyperostosis, and long bone fragility. Histomorphometry shows increased osteoblasts but decreased bone mineralization. Mice with the corresponding variant also show a complex skeletal phenotype distinct from that of Sp7-null mice. The mutation alters the binding specificity of SP7 from AT-rich motifs to a GC-consensus sequence (typical of other SP family members) and produces an aberrant gene expression profile, including increased expression of Col1a1 and endogenous Sp7, but decreased expression of genes involved in matrix mineralization. Our study identifies a pathogenic mechanism in which a mutation in a transcription factor shifts DNA binding specificity and provides important in vivo evidence that the affinity of SP7 for AT-rich motifs, unique among SP proteins, is critical for normal osteoblast differentiation.
NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function

Molecular therapy : the journal of the American Society of Gene Therapy

2022 Jan 31

Fang, F;Zhuang, P;Feng, X;Liu, P;Liu, D;Huang, H;Li, L;Chen, W;Liu, L;Sun, Y;Jiang, H;Ye, J;Hu, Y;
PMID: 35114390 | DOI: 10.1016/j.ymthe.2022.01.035

The lack of neuroprotective treatments for retinal ganglion cells (RGCs) and optic nerve (ON) is a central challenge for glaucoma management. Emerging evidence suggests that redox factor NAD+ decline is a hallmark of aging and neurodegenerative diseases. Supplementation with NAD+ precursors and overexpression of NMNAT1, the key enzyme in the NAD+ biosynthetic process, have significant neuroprotective effects. We first profile the translatomes of RGCs in naive mice and mice with silicone oil-induced ocular hypertension (SOHU)/glaucoma by RiboTag mRNA sequencing. Intriguingly, only NMNAT2, but not NMNAT1 or NMNAT3, is significantly decreased in SOHU glaucomatous RGCs, which we confirm by in situ hybridization. We next demonstrate that AAV2 intravitreal injection-mediated overexpression of long half-life NMNAT2 mutant driven by RGC-specific mouse γ-synuclein (mSncg) promoter restores decreased NAD+ levels in glaucomatous RGCs and ONs. Moreover, this RGC-specific gene therapy strategy delivers significant neuroprotection of both RGC soma and axon and preservation of visual function in the traumatic ON crush model and the SOHU glaucoma model. Collectively, our studies suggest that the weakening of NMNAT2 expression in glaucomatous RGCs contributes to a deleterious NAD+ decline, and that modulating RGC-intrinsic NMNAT2 levels by AAV2-mSncg vector is a promising gene therapy for glaucomatous neurodegeneration.
Analysis of Non-Relapsed and Relapsed Adult Type Granulosa Cell Tumors Suggests Stable Transcriptomes during Tumor Progression

Current Issues in Molecular Biology

2022 Jan 28

Andersson, N;Haltia, U;Färkkilä, A;Wong, S;Eloranta, K;Wilson, D;Unkila-Kallio, L;Pihlajoki, M;Kyrönlahti, A;Heikinheimo, M;
| DOI: 10.3390/cimb44020048

Adult-type granulosa cell tumor (AGCT) is a rare ovarian malignancy characterized by slow growth and hormonal activity. The prognosis of AGCT is generally favorable, but one-third of patients with low-stage disease experience a late relapse, and over half of them die of AGCT. To identify markers that would distinguish patients at risk for relapse, we performed Lexogen QuantSeq 3′ mRNA sequencing on formalin-fixed paraffin-embedded, archival AGCT tissue samples tested positive for the pathognomonic Forkhead Box L2 (FOXL2) mutation. We compared the transcriptomic profiles of 14 non-relapsed archival primary AGCTs (follow-up time 17-26 years after diagnosis) with 13 relapsed primary AGCTs (follow-up time 1.7-18 years) and eight relapsed tumors (follow-up time 2.8-18.9 years). Non-relapsed and relapsed primary AGCTs had similar transcriptomic profiles. In relapsed tumors three genes were differentially expressed: plasmalemma vesicle associated protein (PLVAP) was upregulated (p = 0.01), whereas argininosuccinate synthase 1 (ASS1) (p = 0.01) and perilipin 4 (PLIN4) (p = 0.02) were downregulated. PLVAP upregulation was validated using tissue microarray RNA in situ hybridization. In our patient cohort with extremely long follow-up, we observed similar gene expression patterns in both primary AGCT groups, suggesting that relapse is not driven by transcriptomic changes. These results reinforce earlier findings that molecular markers do not predict AGCT behavior or risk of relapse.
Giant Cell Tumor of Bone Versus Tenosynovial Giant Cell Tumor- Similarities and Differences

International journal of surgical pathology

2022 Jan 31

Kropivšek, L;Pižem, J;Mavčič, B;
PMID: 35098753 | DOI: 10.1177/10668969221076545

Giant cell tumor of bone (GCTB) and tenosynovial giant cell tumor (TGCT) share misleadingly similar names, soft texture and brown color macroscopically, osteoclast-like multinucleated giant cells microscopically and localisation in the musculoskeletal system. However, these two tumor types are biologically and clinically two distinct entities with different natural courses of progression and considerably different modes of surgical and medical treatment. In this article, we provide a detailed update on the similarities and the differences between both tumor types.GCTB is a locally aggressive osteolytic bone tumor, commonly seen in patients in their third decade of life. It usually occurs as a solitary lesion in the meta-epiphyseal region of long bones. It can be diagnosed using plain radiographic imaging, CT radiography or MRI to estimate the tumor extent, soft tissue and joint involvement. GCTB is usually treated with intralesional excision by curettage. Systemically, it can be treated with bisphosphonates and denosumab or radiotherapy.TGCT is a rare, slowly progressing tumor of synovial tissue, affecting the joint, tendon sheath or bursa, mostly seen in middle-aged patients. TGCT is usually not visible on radiographs and MRI is mostly used to enable assessment of potential bone involvement and distinguishing between two TGCT types. Localised TGCT is mostly treated with marginal surgical resection, while diffuse TGCT is optimally treated with total synovectomy and is more difficult to remove. Additionally, radiotherapy, intraarticular injection of radioactive isotopes, anti-TNF-α antibodies and targeted medications may be used.
Vision-dependent specification of cell types and function in the developing cortex

Cell

2022 Jan 20

Cheng, S;Butrus, S;Tan, L;Xu, R;Sagireddy, S;Trachtenberg, JT;Shekhar, K;Zipursky, SL;
PMID: 35063073 | DOI: 10.1016/j.cell.2021.12.022

The role of postnatal experience in sculpting cortical circuitry, while long appreciated, is poorly understood at the level of cell types. We explore this in the mouse primary visual cortex (V1) using single-nucleus RNA sequencing, visual deprivation, genetics, and functional imaging. We find that vision selectively drives the specification of glutamatergic cell types in upper layers (L) (L2/3/4), while deeper-layer glutamatergic, GABAergic, and non-neuronal cell types are established prior to eye opening. L2/3 cell types form an experience-dependent spatial continuum defined by the graded expression of ∼200 genes, including regulators of cell adhesion and synapse formation. One of these genes, Igsf9b, a vision-dependent gene encoding an inhibitory synaptic cell adhesion molecule, is required for the normal development of binocular responses in L2/3. In summary, vision preferentially regulates the development of upper-layer glutamatergic cell types through the regulation of cell-type-specific gene expression programs.
LncRNA IFITM4P promotes immune escape by up-regulating PD-L1 via dual mechanism in oral carcinogenesis

Molecular therapy : the journal of the American Society of Gene Therapy

2022 Jan 17

Shi, L;Yang, Y;Li, M;Li, C;Zhou, Z;Tang, G;Wu, L;Yao, Y;Shen, X;Hou, Z;Jia, H;
PMID: 35051616 | DOI: 10.1016/j.ymthe.2022.01.003

Oral squamous cell carcinoma (OSCC), which is typically preceded by oral leukoplakia (OL), is a common malignancy with poor prognosis. However, the signaling molecules governing this progression remain to be defined. Based on microarray analysis of genes expressed in OL and OSCC samples, we discovered that the long non-coding RNA IFITM4P was highly expressed in OSCC, and ectopic expression or knockdown of IFITM4P resulted in increased or decreased cell proliferation in vitro and in xenografted tumors, respectively. Mechanistically, in the cytoplasm IFITM4P acted as a scaffold to facilitate recruiting SASH1 to bind and phosphorylate TAK1 (Thr187), and in turn to increase the phosphorylation of nuclear factor κB (Ser536) and concomitant induction of PD-L1 expression, resulting in activation of an immunosuppressive program that allows OL cells to escape anti-cancer immunity in cytoplasm. In nucleus, IFITM4P reduced Pten transcription by enhancing the binding of KDM5A to the Pten promoter, thereby upregulating PD-L1 in OL cells. Moreover, mice bearing tumors with high IFITM4P expression had notable therapeutic sensitivity to PD-1 monoclonal antibody (mAb) treatment. Collectively, these data demonstrate that IFITM4P may serve as a new therapeutic target in blockage of oral carcinogenesis, and PD-1 mAb can be an effective reagent to treat OSCC.
Cell Type-Selective Loss of Peroxisomal β-Oxidation Impairs Bipolar Cell but Not Photoreceptor Survival in the Retina

Cells

2022 Jan 04

Swinkels, D;Das, Y;Kocherlakota, S;Vinckier, S;Wever, E;van Kampen, AHC;Vaz, FM;Baes, M;
PMID: 35011723 | DOI: 10.3390/cells11010161

Retinal degeneration is a common feature in peroxisomal disorders leading to blindness. Peroxisomes are present in the different cell types of the retina; however, their precise contribution to retinal integrity is still unclear. We previously showed that mice lacking the central peroxisomal β-oxidation enzyme, multifunctional protein 2 (MFP2), develop an early onset retinal decay including photoreceptor cell death. To decipher the function of peroxisomal β-oxidation in photoreceptors, we generated cell type selective Mfp2 knockout mice, using the Crx promotor targeting photoreceptors and bipolar cells. Surprisingly, Crx-Mfp2-/- mice maintained photoreceptor length and number until the age of 1 year. A negative electroretinogram was indicative of preserved photoreceptor phototransduction, but impaired downstream bipolar cell signaling from the age of 6 months. The photoreceptor ribbon synapse was affected, containing free-floating ribbons and vesicles with altered size and density. The bipolar cell interneurons sprouted into the ONL and died. Whereas docosahexaenoic acid levels were normal in the neural retina, levels of lipids containing very long chain polyunsaturated fatty acids were highly increased. Crx-Pex5-/- mice, in which all peroxisomal functions are inactivated in photoreceptors and bipolar cells, developed the same phenotype as Crx-Mfp2-/- mice. In conclusion, the early photoreceptor death in global Mfp2-/- mice is not driven cell autonomously. However, peroxisomal β-oxidation is essential for the integrity of photoreceptor ribbon synapses and of bipolar cells.
LINC00885 promotes cervical cancer progression through sponging miR-3150b-3p and upregulating BAZ2A

Biology direct

2022 Jan 10

Liu, Y;Chen, J;Zhou, L;Yin, C;
PMID: 35012615 | DOI: 10.1186/s13062-021-00314-6

Cervical cancer (CC) is one of the most common malignancies affecting female worldwide. Long non-coding RNAs (lncRNAs) are increasingly indicated as crucial participants and promising therapeutic targets in human cancers. The main objective of this study was to explore the functions and mechanism of LINC00885 in CC.RT-qPCR and western blot were used to detect RNA and protein levels. Functional and mechanism assays were respectively done for the analysis of cell behaviors and molecular interplays.Long intergenic non-coding RNA 885 (LINC00885) was discovered to be upregulated in CC tissues and cell lines through bioinformatics analysis and RT-qPCR. Overexpression of LINC00885 promoted proliferation and inhibited apoptosis, whereas its silence exerted opposite effects. The cytoplasmic localization of LINC00885 was ascertained and furthermore, LINC00885 competitively bound with miR-3150b-3p to upregulate BAZ2A expression in CC cells. Rescue assays confirmed that LINC00885 regulated CC proliferation and apoptosis through miR-3150b-3p/BAZ2A axis. Finally, we confirmed that LINC00885 aggravated tumor growth through animal experiments.LINC00885 exerted oncogenic function in CC via regulating miR-3150b-3p/BAZ2A axis. These findings suggested LINC00885 might serve as a potential promising therapeutic target for CC patients.
Persistent Ebola Virus Infection within the Male Reproductive Tract is Related to Both Viral Replication Kinetics and Host Response at the Blood-Testis Barrier

SSRN Electronic Journal

2022 Jan 11

Webb, A;Schindell, B;Griffin, B;Soule, G;Siddik, A;Abrenica, B;Memon, H;Su, R;Kobasa, D;Safronetz, D;Kindrachuk, J;
| DOI: 10.2139/ssrn.4000892

Recent outbreaks of Ebola virus linked to chains of transmission from the 2014-2016 West African Ebola virus epidemic suggest a new paradigm for persistent Ebola virus infections as a lasting concern to public health. Cases of Ebola virus disease linked to sexual transmission and detection of Ebola virus in the male reproductive tract long after patients have recovered suggests that Ebola virus persistence occurs in this immune privileged area. However, little is known about Ebola virus cell tropism, viral kinetics, and host response to infection in the testis. In this study, we challenged immunocompromised mice and testicular tissue cultures with wild type Ebola virus. We utilized RT-qPCR and ISH to detect and quantify Ebola virus in the testis. We also employed RNAseq analysis to measure the transcriptomic response of specific testicular cell types to Ebola virus infection. Our results indicate that Ebola virus productively infects the cells at the blood-testis barrier, and that the interstitial space is more susceptible to infection compared to blood-testis barrier itself. In addition, the Sertoli cells that make up the physical structure of the blood-testis barrier maintain greater viability during Ebola virus infection, and this results from nonstandard immune response that prioritizes inhibited viral entry/replication and increased cell homeostatic activity. Our findings reinforce the need to further investigate viral persistence in the male reproductive tract as a reservoir for ongoing and future outbreaks of Ebola virus disease.
SP1-induced lncRNA DUBR promotes stemness and oxaliplatin resistance of hepatocellular carcinoma via E2F1-CIP2A feedback

Cancer letters

2021 Dec 25

Liu, S;Bu, X;Kan, A;Luo, L;Xu, Y;Chen, H;Lin, X;Lai, Z;Wen, D;Huang, L;Shi, M;
PMID: 34958891 | DOI: 10.1016/j.canlet.2021.12.026

Oxaliplatin-based chemotherapy is widely used to treat advanced hepatocellular carcinoma (HCC), but many patients develop drug resistance that leads to tumor recurrence. Cancer stem cells (CSCs) are known to contribute to chemoresistance, the underlying mechanism, however, remains largely unknown. In this study, we discovered a specificity protein 1 (SP1)-induced long noncoding RNA--DPPA2 upstream binding RNA (DUBR) and its high expression in HCC tissues and liver CSCs. DUBR was associated with HCC progression and poor chemotherapy response. Moreover, DUBR facilitated the stemness and oxaliplatin resistance of HCC in vitro and in vivo. Mechanistically, DUBR upregulated cancerous inhibitor of protein phosphatase 2A (CIP2A) expression through E2F1-mediated transcription regulation. DUBR also exerted function by binding microRNA (miR)-520d-5p as a competing endogenous RNA to upregulate CIP2A at mRNA level. CIP2A, in turn, stabilized E2F1 protein and activated the Notch1 signaling pathway, thereby increasing the stemness feature of HCC and leading to chemoresistance. In conclusion, we identified SP1/DUBR/E2F1-CIP2A as a critical axis to activate the Notch1 signaling pathway and promote stemness and chemoresistance of HCC. Therefore, DUBR could be a potential target in HCC treatment.
Neuropsychiatric manifestations of COVID-19, potential neurotropic mechanisms, and therapeutic interventions

Translational psychiatry

2021 Sep 30

Han, Y;Yuan, K;Wang, Z;Liu, WJ;Lu, ZA;Liu, L;Shi, L;Yan, W;Yuan, JL;Li, JL;Shi, J;Liu, ZC;Wang, GH;Kosten, T;Bao, YP;Lu, L;
PMID: 34593760 | DOI: 10.1038/s41398-021-01629-8

The coronavirus disease 2019 (COVID-19) pandemic has caused large-scale economic and social losses and worldwide deaths. Although most COVID-19 patients have initially complained of respiratory insufficiency, the presence of neuropsychiatric manifestations is also reported frequently, ranging from headache, hyposmia/anosmia, and neuromuscular dysfunction to stroke, seizure, encephalopathy, altered mental status, and psychiatric disorders, both in the acute phase and in the long term. These neuropsychiatric complications have emerged as a potential indicator of worsened clinical outcomes and poor prognosis, thus contributing to mortality in COVID-19 patients. Their etiology remains largely unclear and probably involves multiple neuroinvasive pathways. Here, we summarize recent animal and human studies for neurotrophic properties of severe acute respiratory syndrome coronavirus (SARS-CoV-2) and elucidate potential neuropathogenic mechanisms involved in the viral invasion of the central nervous system as a cause for brain damage and neurological impairments. We then discuss the potential therapeutic strategy for intervening and preventing neuropsychiatric complications associated with SARS-CoV-2 infection. Time-series monitoring of clinical-neurochemical-radiological progress of neuropsychiatric and neuroimmune complications need implementation in individuals exposed to SARS-CoV-2. The development of a screening, intervention, and therapeutic framework to prevent and reduce neuropsychiatric sequela is urgently needed and crucial for the short- and long-term recovery of COVID-19 patients.

Pages

  • « first
  • ‹ previous
  • …
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • …
  • next ›
  • last »
X
Description
sense
Example: Hs-LAG3-sense
Standard probes for RNA detection are in antisense. Sense probe is reverse complent to the corresponding antisense probe.
Intron#
Example: Mm-Htt-intron2
Probe targets the indicated intron in the target gene, commonly used for pre-mRNA detection
Pool/Pan
Example: Hs-CD3-pool (Hs-CD3D, Hs-CD3E, Hs-CD3G)
A mixture of multiple probe sets targeting multiple genes or transcripts
No-XSp
Example: Hs-PDGFB-No-XMm
Does not cross detect with the species (Sp)
XSp
Example: Rn-Pde9a-XMm
designed to cross detect with the species (Sp)
O#
Example: Mm-Islr-O1
Alternative design targeting different regions of the same transcript or isoforms
CDS
Example: Hs-SLC31A-CDS
Probe targets the protein-coding sequence only
EnEmProbe targets exons n and m
En-EmProbe targets region from exon n to exon m
Retired Nomenclature
tvn
Example: Hs-LEPR-tv1
Designed to target transcript variant n
ORF
Example: Hs-ACVRL1-ORF
Probe targets open reading frame
UTR
Example: Hs-HTT-UTR-C3
Probe targets the untranslated region (non-protein-coding region) only
5UTR
Example: Hs-GNRHR-5UTR
Probe targets the 5' untranslated region only
3UTR
Example: Rn-Npy1r-3UTR
Probe targets the 3' untranslated region only
Pan
Example: Pool
A mixture of multiple probe sets targeting multiple genes or transcripts

Enabling research, drug development (CDx) and diagnostics

Contact Us
  • Toll-free in the US and Canada
  • +1877 576-3636
  • 
  • 
  • 
Company
  • Overview
  • Leadership
  • Careers
  • Distributors
  • Quality
  • News & Events
  • Webinars
  • Patents
Products
  • RNAscope or BaseScope
  • Target Probes
  • Controls
  • Manual assays
  • Automated Assays
  • Accessories
  • Software
  • How to Order
Research
  • Popular Applications
  • Cancer
  • Viral
  • Pathways
  • Neuroscience
  • Other Applications
  • RNA & Protein
  • Customer Innovations
  • Animal Models
Technology
  • Overview
  • RNA Detection
  • Spotlight Interviews
  • Publications & Guides
Assay Services
  • Our Services
  • Biomarker Assay Development
  • Cell & Gene Therapy Services
  • Clinical Assay Development
  • Tissue Bank & Sample Procurement
  • Image Analysis
  • Your Benefits
  • How to Order
Diagnostics
  • Diagnostics
  • Companion Diagnostics
Support
  • Getting started
  • Contact Support
  • Troubleshooting Guide
  • FAQs
  • Manuals, SDS & Inserts
  • Downloads
  • Webinars
  • Training Videos

Visit Bio-Techne and its other brands

  • bio-technie
  • protein
  • bio-spacific
  • rd
  • novus
  • tocris
© 2025 Advanced Cell Diagnostics, Inc.
  • Terms and Conditions of Sale
  • Privacy Policy
  • Security
  • Email Preferences
  • 
  • 
  • 

For Research Use Only. Not for diagnostic use. Refer to appropriate regulations. RNAscope is a registered trademark; and HybEZ, EZ-Batch and DNAscope are trademarks of Advanced Cell Diagnostics, Inc. in the United States and other countries. All rights reserved. ©2025 Advanced Cell Diagnostics, Inc.

 

Contact Us / Request a Quote
Download Manuals
Request a PAS Project Consultation
Order online at
bio-techne.com
OK
X
Contact Us

Complete one of the three forms below and we will get back to you.

For Quote Requests, please provide more details in the Contact Sales form below

  • Contact Sales
  • Contact Support
  • Contact Services
  • Offices

Advanced Cell Diagnostics

Our new headquarters office starting May 2016:

7707 Gateway Blvd.  
Newark, CA 94560
Toll Free: 1 (877) 576-3636
Phone: (510) 576-8800
Fax: (510) 576-8798

 

Bio-Techne

19 Barton Lane  
Abingdon Science Park
Abingdon
OX14 3NB
United Kingdom
Phone 2: +44 1235 529449
Fax: +44 1235 533420

 

Advanced Cell Diagnostics China

20F, Tower 3,
Raffles City Changning Office,
1193 Changning Road, Shanghai 200051

021-52293200
info.cn@bio-techne.com
Web: www.acdbio.com/cn

For general information: Info.ACD@bio-techne.com
For place an order: order.ACD@bio-techne.com
For product support: support.ACD@bio-techne.com
For career opportunities: hr.ACD@bio-techne.com

See Distributors
×

You have already Quick ordered an Item in your cart . If you want to add a new item , Quick ordered Item will be removed form your cart. Do You want to continue?

OK Cancel
Need help?

How can we help you?